AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	5/16/2011 11:15:50 AM
	Read Replies (1) of 2173

AP: THE COMPLAINT: Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product. AMYLIN'S GOAL: San Diego-based Amylin plans to continue working with Lilly, but it wants to keep Lilly from using the same sales force to sell both its product and the Boehringer product linagliptin, which goes by the brand name Tradjenta. LILLY'S RESPONSE: Indianapolis-based Lilly said the lawsuit is without merit, and it will vigorously defend itself.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next